This generic drug company has seen no estimate revision over the past 30 days and its Zacks Consensus Estimate remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Acasti Pharma has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the same sector include Akorn, Inc. (AKRX), Mallinckrodt plc (MNK) and Celator Pharmaceuticals, Inc. (CPXX). While Akorn and Mallinckrodt hold a Zacks Rank #1 (Strong Buy), Celator Pharmaceuticals carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment